XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Note 15 - Share-based Compensation | 6 Months Ended
--- | ---
Mar. 31, 2024
Notes to Financial Statements |
Share-Based Payment Arrangement [Text Block] |
15. | SHARE-BASED COMPENSATION
Stock option plans The Amended and Restated 2015 Equity Incentive Plan (“2015 Equity Plan”) was adopted by the Company’s Board of Directors on December 6, 2016 and approved by the Company’s stockholders on March 14, 2017. The 2015 Equity Plan was amended by the Company’s Board of Directors on December 8, 2020, to increase the number of shares authorized for issuance from 5,000,000 to 10,000,000. On March 16, 2021, the Company’s stockholders approved the plan amendment. The 2015 Equity Plan authorizes the issuance of stock options, restricted stock, stock appreciation rights, restricted stock units (“RSUs”) and performance awards, to an aggregate of 10,000,000 new shares of common stock to employees, directors, advisors or consultants. As of March 31, 2024, there were options and restricted stock units outstanding covering 3,749,366 shares of common stock under the 2015 Equity Plan, respectively, and 2,463,064 shares of common stock available for grant, for a total of 6,212,430 shares of common stock authorized and unissued under the equity plans. Share-based compensation The Company’s employee stock options have various restrictions that reduce option value, including vesting provisions and restrictions on transfer and hedging, among others, and are often exercised prior to their contractual maturity. There were 897,250 stock options granted during the six months ended March 31, 2024. There were 1,806,500 stock options granted during the six months ended March 31, 2023. The weighted average estimated fair value of employee stock options granted during the six months ended March 31, 2024 and 2023, was calculated using the Black-Scholes option-pricing model with the following weighted average assumptions (annualized percentages):
|  | Six months ended |
|  | March 31, |
|  | 2024 |  |  | 2023 |
Volatility |  |  | 57.8% |  |  |  | 52.1% |
Risk-free interest rate |  |  | 4.3% |  |  |  | 4.0% |
Dividend yield |  |  | 0.0% |  |  |  | 0.0% |
Expected term in years |  |  | 4.2 |  |  |  | 5.8 |
Expected volatility is based on the historical volatility of the Company’s common stock over the period commensurate with the expected term of the options. The risk-free interest rate is based on rates published by the Federal Reserve Board. The contractual term of the options was seven years. The expected term is based on observed and expected time to post-vesting exercise. The expected forfeiture rate is based on past experience and employee retention data. Forfeitures are estimated at the time of the grant and revised in subsequent periods if actual forfeitures differ from those estimates. Such revision adjustments to expense will be recorded as a cumulative adjustment in the period in which the estimate is changed. The Company has not paid a dividend in fiscal 2024 and did not pay a dividend in fiscal 2023. As of March 31, 2024, there was approximately $1,881 of total unrecognized compensation costs related to outstanding employee stock options. This amount is expected to be recognized over a weighted average period of 2.3 years. To the extent the forfeiture rate is different from what the Company anticipated, stock-based compensation related to these awards will be different from the Company’s expectations. Performance-based stock options On August 10, 2022, the Company granted PVOs to purchase up to 750,000 shares of the Company’s common stock to a key member of management, with a contractual term of seven years. During the year ended September 30, 2023, these options were forfeited due to a voluntary termination of employment. The Company did not record compensation expense related to these options, On October 8, 2022, the Company awarded performance-based stock options to purchase 800,000 shares of the Company’s common stock to a key executive, with a contractual term of seven years. Vesting is based upon the achievement of certain performance criteria for each of fiscal 2025 and 2026 including a minimum free cash flow margin and net revenue targets. Additionally, vesting is subject to the executive being employed by the Company at the time the Company achieves such financial targets. The Company has not recorded compensation expense related to these options. On March 20, 2023, the Company granted PVOs to purchase up to 450,000 shares of the Company’s stock to a key member of management with a contractual term of seven years. Vesting is based upon the achievement of certain performance criteria for each of the first three twelve-month periods following the employee’s start date, including targets related to growth in the institutional ownership of the Company’s common stock and growth in the trading volume of the Company’s common stock during such periods. Additionally, vesting is subject to the employee being employed by the Company on each of the first three anniversaries of the employee’s start date. 225,000 of these options contain a market-based vesting condition and accounting principles do not require the market condition to be achieved in order for compensation expense to be recognized. The Company recorded $124 of compensation expense related to these options during the six months ended March 31, 2024. The Company did not grant any PVO’s during the six months ended March 31, 2024. Restricted stock units During fiscal 2021, 145,950 RSUs were granted to employees that will vest over three years on the anniversary date of the grant. These were issued at a market value of $989, which have and will be expensed on a straight-line basis over the three-year life of the grants. On November 1, 2022, 10,000 RSUs were granted to a non-employee advisor that vested on the first anniversary of the grant date. These were issued at a market value of $29, which were expensed on a straight-line basis though the November 1, 2023 vest date. On November 1, 2023, 10,000 RSUs were granted to a non-employee advisor that vested on the first anniversary of the grant date. These were issued at a market value of $17, which have and will be expensed on a straight-line basis though the November 1, 2024, vest date. On March 14, 2023, each non-employee member of the Board of Directors received a grant of 30,000 RSUs that vested on the first anniversary of the grant date. These RSUs were granted at a market value of $417 and have been expensed on a straight-line basis through the March 14, 2024, vest date. On March 14, 2024, each non-employee member of the Board of Directors received a grant of 30,000 RSUs that will vest on the first anniversary of the grant date. These RSUs were granted at a market value of $215 and have and will be expensed on a straight-line basis through the March 14, 2025, vest date. On February 14, 2023, 145,600 RSUs were granted to employees that will vest over three years on the anniversary date of the grant. These RSUs were issued at a market value of $582, which have and will be expensed on a straight-line basis over the three-year life of the grants. Compensation expense for RSUs was $343 and $350 for the three months ended March 31. 2024 and 2023, respectively. Compensation expense for RSUs was $571 and $586 for the six months ended March 31. 2024 and 2023, respectively. As of March 31, 2024, there was approximately $674 of total unrecognized compensation costs related to outstanding RSUs. This amount is expected to be recognized over a weighted average period of 1.0 years. A summary of the Company’s RSUs as of March 31, 2024 is presented below:
` |  | Number of Shares |  |  | Weighted Average Grant Date Fair Value |
Outstanding September 30, 2023 |  |  | 379,597 |  |  | $ | 3.94 |
Granted |  |  | 238,711 |  |  | $ | 2.06 |
Released |  |  | (239,233 | ) |  | $ | 3.99 |
Forfeited/cancelled |  |  | (7,533 | ) |  | $ | 4.08 |
Outstanding March 31, 2024 |  |  | 371,542 |  |  | $ | 2.69 |
Stock option summary information A summary of the activity in options to purchase the capital stock of the Company as of March 31, 2024 is presented below:
|  | Number of Shares |  |  | Weighted Average Exercise Price |
Outstanding September 30, 2023 |  |  | 2,904,522 |  |  | $ | 3.19 |
Granted |  |  | 897,250 |  |  | $ | 1.70 |
Forfeited/expired |  |  | (423,948 | ) |  | $ | 2.85 |
Exercised |  |  | - |  |  | $ | - |
Outstanding March 31, 2024 |  |  | 3,377,824 |  |  | $ | 2.84 |
Exerciseable March 31, 2024 |  |  | 1,097,178 |  |  | $ | 3.49 |
Options outstanding are exercisable at prices ranging from $1.51 to $8.03 per share and expire over the period from 2024 to 2030 with an average life of 5.1 years. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2024 was $605 and $64, respectively. The aggregate intrinsic value represents the difference between the Company’s closing stock price on the last day of trading for the quarter, which was $2.37 per share, and the exercise price multiplied by the number of applicable options. The total intrinsic value of stock options exercised during the six months ended March 31, 2024 was $0 and proceeds from these exercises was $0. The total intrinsic value of stock options exercised during the six months ended March 31, 2023 was $147 and proceeds from these exercises was $86. The following table summarized information about stock options outstanding as of March 31, 2024:
|  |  |  |  |  | Weighted Average |  |  | Weighted Average |  |  |  |  |  |  | Weighted Average |
Range of |  | Number |  |  | Remaining |  |  | Exercise |  |  | Number |  |  | Exercise |
Exercise Prices |  | Outstanding |  |  | Contractual Term |  |  | Price |  |  | Exercisable |  |  | Price |
$1.51 | - | $1.76 |  |  | 910,375 |  |  |  | 6.00 |  |  | $ | 1.71 |  |  |  | 103,125 |  |  | $ | 1.75 |
$2.64 | - | $2.68 |  |  | 88,000 |  |  |  | 6.26 |  |  | $ | 2.67 |  |  |  | - |  |  | $ | - |
$2.69 | - | $2.69 |  |  | 1,031,250 |  |  |  | 5.37 |  |  | $ | 2.69 |  |  |  | 131,250 |  |  | $ | 2.69 |
$3.09 | - | $8.03 |  |  | 1,348,199 |  |  |  | 4.23 |  |  | $ | 3.73 |  |  |  | 862,803 |  |  | $ | 3.82 |
|  |  | 3,377,824 |  |  |  | 5.11 |  |  | $ | 2.84 |  |  |  | 1,097,178 |  |  | $ | 3.49 |
The Company recorded $181 and $163 of stock option compensation expense for employees, directors and consultants for the three months ended March 31, 2024 and 2023, respectively. The Company recorded $399 and $385 of stock option compensation expense for employees, directors and consultants for the six months ended March 31, 2024 and 2023, respectively. Share-based compensation The Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:
|  | Three Months Ended |  |  | Six Months Ended |
|  | March 31, |  |  | March 31, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Cost of revenues |  | $ | 28 |  |  | $ | 19 |  |  | $ | 42 |  |  | $ | 29 |
Selling, general and administrative |  |  | 439 |  |  |  | 453 |  |  |  | 827 |  |  |  | 831 |
Research and development |  |  | 57 |  |  |  | 41 |  |  |  | 101 |  |  |  | 73 |
|  | $ | 524 |  |  | $ | 513 |  |  | $ | 970 |  |  | $ | 933 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration